At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 15 enrolled
Drug / intervention
TA-CIN (arm) +1 morebiological
Likely dose
TA-CIN (arm) 100µgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Pilot Clinical Trial Assessing the Safety and Feasibility of Intramuscular Administration of the TA-CIN Vaccine as Adjuvant Therapy for Patients With History of HPV16 Associated Cervical Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins·interventional·Posted Apr 1, 2015·Updated Jan 29, 2026
In Brief
A Phase 1 clinical trial evaluating TA-CIN (arm) and TA-CIN (thigh) for HPV16 Associated Cervical Cancer. Completed, enrolled 15 participants across 2 sites.
Detailed Summary
This study will be looking at what dose of the TA-CIN vaccine is safe and effective in patients with a history of HPV16-associated cervical cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHPV16 Associated Cervical Cancer
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI), PapiVax Biotech, Inc.
Timeline
Phase 1CompletedFinished
201520162017201820192020202120222023202420252026
First PostedApr 2015
Enrollment StartApr 2019
Primary CompletionDec 2024
Study CompletionJan 2025
TodayJul 2026
First PostedApr 1, 2015
Enrollment StartApr 4, 2019
Primary CompletionDec 31, 2024
Study CompletionJan 31, 2025
TodayJul 2, 2026
Enrollment to primary: 5.7 yearsPosted 11.3 years ago
Interventions
TA-CIN (arm)biological
TA-CIN vaccine 100µg IM in the arm at Week 1, 5, and 9.
TA-CIN (thigh)biological
TA-CIN vaccine 100µg IM in the arm at Week 1, 5, and 9.